Top Page
Strata Skin Sciences
(NASDAQ:SSKN)
Strata Skin Sciences (SSKN) vs. SPDR S&P 500 ETF (SPY)
Strata Skin Sciences Business Overview & Revenue Model
Strata Skin Sciences Earnings Call Summary
Strata Skin Sciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.98M | 33.56M | 33.36M | 36.16M | 29.98M | 23.09M |
| Gross Profit | 17.89M | 19.08M | 18.46M | 21.77M | 19.85M | 14.13M |
| EBITDA | -4.34M | -2.84M | -3.38M | 1.13M | 1.73M | -15.00K |
| Net Income | -11.04M | -10.09M | -10.83M | -5.55M | -2.71M | -4.41M |
Balance Sheet | ||||||
| Total Assets | 30.72M | 36.16M | 42.02M | 52.27M | 46.59M | 46.78M |
| Cash, Cash Equivalents and Short-Term Investments | 7.08M | 7.26M | 6.78M | 5.43M | 12.59M | 10.60M |
| Total Debt | 16.31M | 16.44M | 15.63M | 8.44M | 8.03M | 10.88M |
| Total Liabilities | 29.40M | 31.18M | 29.33M | 30.44M | 21.18M | 20.89M |
| Stockholders Equity | 1.31M | 4.97M | 12.69M | 21.83M | 25.41M | 25.89M |
Cash Flow | ||||||
| Free Cash Flow | -3.51M | -1.45M | -5.54M | -4.66M | -2.15M | -63.00K |
| Operating Cash Flow | -1.85M | 188.00K | -519.00K | -1.11M | 1.51M | 2.10M |
| Investing Cash Flow | -1.66M | -1.64M | -5.02M | -4.18M | -7.13M | -2.16M |
| Financing Cash Flow | 2.19M | 1.93M | 6.86M | -500.00K | 92.00K | 2.55M |
Strata Skin Sciences Technical Analysis
Strata Skin Sciences Risk Analysis
Strata Skin Sciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $90.80M | 13.01 | 4.34% | ― | 3.36% | -21.15% | |
59 Neutral | $84.18M | 58.92 | 3.64% | ― | 16.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $9.66M | -0.61 | -207.19% | ― | -5.19% | -0.81% | |
42 Neutral | $48.10M | ― | -96.15% | ― | -8.97% | 47.29% | |
40 Underperform | $11.83M | -0.31 | -204.04% | ― | -60.89% | 94.49% |
Strata Skin Sciences Corporate Events
STRATA Skin Sciences, Inc. is a medical technology company that specializes in developing and marketing innovative products for the treatment of dermatologic conditions, focusing on in-office solutions for conditions such as psoriasis, vitiligo, and acne.
On November 13, 2025, STRATA Skin Sciences announced its financial results for the third quarter of 2025, reporting a decline in total revenue by approximately $1.9 million due to international market instability. Despite this, the company made significant progress in expanding CPT codes for reimbursement, which is expected to triple the covered patient population in the US. The company also reported positive developments in its ongoing lawsuit against LaserOptek, which could lead to increased revenue. STRATA’s gross margin remained stable at 60%, and the company ended the quarter with $7.1 million in cash.
The most recent analyst rating on (SSKN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
STRATA Skin Sciences, Inc. announced an equity distribution agreement with Ladenburg Thalmann & Co. Inc. for the sale of up to $11 million in common stock shares. This agreement, initially registered in 2021 and updated in 2024, allows for future offerings, potentially impacting the company’s market operations and investor relations.
The most recent analyst rating on (SSKN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
Strata Skin Sciences, Inc. received a deficiency notification from Nasdaq on August 22, 2025, for not meeting the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market. On October 13, 2025, Nasdaq accepted the company’s compliance plan, granting an extension until February 16, 2026, to meet the requirement. The company is exploring options to regain compliance, but failure to do so could result in delisting, with the possibility to appeal any delisting decision.
The most recent analyst rating on (SSKN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
On September 4, 2025, STRATA Skin Sciences announced the closing of a registered direct offering, issuing 1,097,547 shares of common stock at $2.204 per share, raising approximately $2.42 million in gross proceeds. The funds are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.
The most recent analyst rating on (SSKN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
On September 2, 2025, Strata Skin Sciences entered into Securities Purchase Agreements with institutional investors to issue 1,097,547 shares of common stock at $2.204 per share, raising approximately $2.4 million in a registered direct offering. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent, and the proceeds are intended for general corporate and working capital purposes. The offering is expected to close on or around September 4, 2025, and is made under a shelf registration statement filed with the SEC.
The most recent analyst rating on (SSKN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
The recent earnings call for Strata Skin Sciences presented a mixed outlook, reflecting both promising developments and notable challenges. On the positive side, there was significant progress with the expansion of CPT codes and increased device placements. However, the company also faced substantial hurdles, including revenue declines and disruptions in international markets. Despite efforts to broaden the market and improve reimbursement rates, financial performance was hampered by legal expenses and decreased revenues from international and equipment sales.
On August 19, 2025, Strata Skin Sciences received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company has until October 3, 2025, to submit a compliance plan, with the possibility of a 180-day extension if accepted. The notice does not immediately affect the company’s stock listing, but failure to comply could lead to delisting, although the company can appeal such a decision.
The most recent analyst rating on (SSKN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
On August 18, 2025, Strata Skin Sciences announced an investor presentation highlighting its strategic initiatives and financial performance. The company reported operational cash flow positivity in 2024 and anticipates significant market expansion by January 2026 due to a historic CPT code expansion. This expansion could unlock over 30 million potential patients for new indications, enhancing revenue opportunities. Additionally, a lawsuit against LaserOptek could potentially bolster Strata’s cash position, reducing competition in the market.
The most recent analyst rating on (SSKN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
STRATA Skin Sciences, Inc. is a medical technology company specializing in the development and marketing of innovative products for treating dermatologic conditions, including psoriasis and vitiligo, using technologies like the XTRAC excimer laser.